Press Release Jan 5 2022: "Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones"

[jeffreyn]

Key Business and Clinical milestones expected in 2022:

- Continue Phase 1 dose escalation of IkT-148009 in older and elderly healthy volunteers;

- Complete first two cohorts in Phase 1b study of IkT-148009 in patients with Parkinson's Disease;

- Submit complete chronic toxicology data for IkT-148009 to the U.S. Food and Drug Administration (FDA) in the first quarter of 2022;

- Meet with the FDA to discuss the development program of IkT-148009 as a treatment for Parkinson's disease;

- Initiate Phase 2a clinical study for IkT-148009 in patients with Parkinson's Disease;

- ...

inhibikase.com/news/press-r...

For background information on Inhibikase and IkT-148009, see this earlier thread:

healthunlocked.com/cure-par...